Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSIRIS-1: Ondansetron for Prevention of Patient Self-Inflicted Lung Injury in ARDS
NCT07588217Phase 3Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ondansetron in acute respiratory distress syndrome (ARDS). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ondansetron
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07588217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588217.